189 results
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
22 Mar 24
Moleculin Reports Full Year 2023 Financial Results
4:08pm
Exhibit 99.1
Moleculin Reports Full Year 2023 Financial Results
– Year marked by growing body of positive Annamycin efficacy and safety clinical … press release just prior.
“Over the course of 2023 we established a significant growing body of positive clinical and encouraging safety data
424B3
MBRX
Moleculin Biotech Inc
16 Feb 24
Prospectus supplement
5:19pm
or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise … to establish the product candidate’s safety and effectiveness for each desired indication. NDAs must also include significant information regarding
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
15 Feb 24
Regulation FD Disclosure
9:15am
changed regarding Annamycin. Can you describe why that is?
It really has, Jenene. Until last year, we were grinding away to establish safety
8-K
EX-99.1
yt0ja9umz1 j1
24 Jan 24
Regulation FD Disclosure
8:50am
8-K
EX-3.1
ceh kr2gz
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-10.1
dwbcqkclo9lc
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
a5gqc
13 Nov 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
qsv9qm
13 Nov 23
Moleculin Reports Third Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
p417k1krkjlaoo7hcl
6 Nov 23
Regulation FD Disclosure
8:35am
8-K
EX-99.1
uokjf4md6s
17 Oct 23
Regulation FD Disclosure
9:00am
8-K
EX-99.1
dnye4cx yknpct6c6g
2 Oct 23
Regulation FD Disclosure
8:40am
8-K
EX-99.1
cx26xuftxtni
21 Sep 23
Regulation FD Disclosure
8:50am
8-K
EX-99.1
mgk4e91t773wzl0c64
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
EX-3.1
gcrkig1
21 Aug 23
Amendments to Articles of Incorporation or Bylaws
5:17pm
8-K
EX-99.1
zchbkgql9n3r3 gni6
10 Aug 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:05pm